Emilia Balcer

Ms. Emilia Balcer

National Centre for Nuclear Research, Poland
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Emilia BalcerEmilia Balcer
Emilia Balcer
MSMonika Sobiech
Monika Sobiech
PLPiotr Luliński
Piotr Luliński
Simultaneous diagnostics and targeted therapy provide a theranostic approach, an instrument of personalized medicine—one of the most-promising trends in current medicine. Except for the appropriate drug used during the treatment, a strong focus is put on the development of effective drug carriers. Among the various materials applied in the production of drug carriers, molecularly imprinted polymers (MIPs) are one of the candidates with great potential for use in theranostics. MIP properties such as chemical and thermal stability, together with capability to integrate with other materials are important in the case of diagnostics and therapy. Moreover, the MIP specificity, which is important for targeted drug delivery and bioimaging of particular cells, is a result of the preparation process, conducted in the presence of the template molecule, which often is the same as the target compound. This review focused on the application of MIPs in theranostics. As a an introduction, the current trends in theranostics are described prior to the characterization of the concept of molecular imprinting technology. Next, a detailed discussion of the construction strategies of MIPs for diagnostics and therapy according to targeting and theranostic approaches is provided. Finally, frontiers and future prospects are presented, stating the direction for further development of this class of materials.

5 December 2021 in Energies
Verified
Journal Article
Open access
PDF file
MMMarek Migdal
Marek Migdal
Emilia BalcerEmilia Balcer
Emilia Balcer
ŁBŁukasz Bartosik
Łukasz Bartosik
LBLukasz BAK
Lukasz BAK
ACAgnieszka Celińska
Agnieszka Celińska
MWMarcin Wójcik
Marcin Wójcik
The MARIA research reactor is designed and operated as a multipurpose nuclear installation, combining material testing, neutron beam experiments, and medical and industrial radionuclide production, including molybdenum-99 (99Mo). Recently, after fuel conversion to LEU and rejuvenation of the staff while maintaining their experience, MARIA has been used to respond to the increased interest of the scientific community in advanced nuclear power studies, both fission and fusion. In this work, we would like to introduce MARIA’ s capabilities in the irradiation technology field and how it can serve future nuclear research worldwide.

10 September 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Emilia BalcerEmilia Balcer
Emilia Balcer
JGJoanna Giebultowicz
Joanna Giebultowicz
MSMałgorzata Sochacka
Małgorzata Sochacka
Anna RuszczynskaAnna Ruszczynska
Anna Ruszczynska
MMMagdalena Muszynska
Magdalena Muszynska
EBEwa Bulska
Ewa Bulska
Boron has gained significant attention in medical research due to its B-10 isotope’s high cross section for the reaction with thermal neutrons, generating ionizing particles that can eliminate cancer cells, propelling the development of boron neutron capture therapy (BNCT) for cancer treatment. The compound 4-borono-L-phenylalanine (BPA) has exhibited potential in BNCT clinical trials. Enhancing BPA uptake in cells involves proposing L-amino acid preloading. This study introduces a novel analytical strategy utilizing ICP-MS and single cell ICP-MS (SC-ICP-MS) to assess the effectiveness of L-tyrosine and L-phenylalanine preloading on human non-small cell lung carcinoma (A549) and normal Chinese hamster lung fibroblast (V79-4) models, an unexplored context. ICP-MS outcomes indicated that L-tyrosine and L-phenylalanine pre-treatment increased BPA uptake in V79-4 cells by 2.04 ± 0.74-fold (p = 0.000066) and 1.46 ± 0.06-fold (p = 0.000016), respectively. Conversely, A549 cells manifested heightened BPA uptake solely with L-tyrosine preloading, with a factor of 1.24 ± 0.47 (p = 0.028). BPA uptake remained higher in A549 compared to V79-4 regardless of preloading. SC-ICP-MS measurements showcased noteworthy boron content heterogeneity within A549 cells, signifying diverse responses to BPA exposure, including a subset with notably high BPA uptake. This study underscores SC-ICP-MS’s utility in precise cellular boron quantification, validating cellular BPA uptake’s heterogeneity.

24 July 2023 in Polymers
Verified
Journal Article
Open access
PDF file
Emilia BalcerEmilia Balcer
Emilia Balcer
MSMonika Sobiech
Monika Sobiech
JGJoanna Giebultowicz
Joanna Giebultowicz
MSMałgorzata Sochacka
Małgorzata Sochacka
PLPiotr Luliński
Piotr Luliński
The aim of this study was to create molecularly imprinted polymers (MIPs) that are specific towards 4-borono-L-phenylalanine (BPA) to serve as boron compound carriers. The honeycomb-like MIPs were characterized in the matter of adsorption properties, morphology, structure, and cytotoxicity towards A549 and V79-4 cell lines. The honeycomb-like MIP composed from methacrylic acid and ethylene glycol dimethacrylate was characterized by a binding capacity of 330.4 ± 4.6 ng g−1 and an imprinting factor of 2.04, and its ordered, porous morphology was confirmed with scanning electron microscopy. The theoretical analysis revealed that the coexistence of different anionic forms of the analyte in basic solution might lower the binding capacity of the MIP towards BPA. The release profiles from the model phosphate buffer saline showed that only 0 to 4.81% of BPA was released from the MIP within the time frame of two hours, furthermore, the obtained material was considered non-cytotoxic towards tested cell lines. The results prove that MIPs can be considered as effective BPA delivery systems for biomedical applications and should be investigated in further studies.

7 January 2020 in Prospects in Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
Emilia BalcerEmilia Balcer
Emilia Balcer
MMMaciej Mazur
Maciej Mazur
Nanomedycyna jest obecnie jedną z najszybciej rozwijających się dziedzin nanotechnologii, znajdującą coraz więcej zastosowań w walce z chorobami nowotworowymi. Nanocząstki złota, ze względu na swoje unikalne właściwości optyczne i chemiczne, cieszą się rosnącym zainteresowaniem naukowców. Do zalet nanocząstek złota należą między innymi wysoki stosunek powierzchni do objętości cząstki, duże możliwości modyfikacji ich powierzchni, czy też występowanie efektu wzmocnionej przepuszczalności i retencji, pozwalającego na bardziej efektywną i selektywną akumulację leku w miejscach zmienionych nowotworowo. W pracy krótko omówiono charakterystykę fizykochemiczną nanocząstek złota oraz przedstawiono ich wybrane zastosowania zarówno w diagnostyce, jak i terapii chorób nowotworowych.